2016-06-16 10:42 ET - News Release
Mr. James Howard-Tripp reports
GENENEWS MEETS TSX CONTINUED LISTING REQUIREMENTS
The Toronto Stock Exchange has completed its remedial review process and determined that GeneNews Ltd. meets the TSX's continued listing requirements.
"The last six to 12 months have been a challenging time for both the company and its shareholders. Over that time, GeneNews has bought out its IDL partners, reorganized operations and cut costs, raised additional financing, and, with a new business model and partner in JTS, can now put our full effort behind building the business," said James R. Howard-Tripp, executive chairman of GeneNews. "We are focused on providing diagnostic services to hospitals, clinically integrated networks, large physician groups and other health care organizations so that our blood-based, early cancer diagnostic tests aid in the risk stratification of patients so that those with highest risk are prioritized for advanced diagnosis and, if needed, treatment. We look forward to announcing agreements with these groups as they are secured.
"We are also pleased that GeneNews' listing on Canada's premiere stock exchange will continue to provide its shareholders with access to a well-regulated market and liquidity for its common shares," commented Mr. Howard-Tripp.
We seek Safe Harbor.